Skip to main content

Can you take Argatroban with Avapritinib?

1 drug interaction and 11 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Major drug interactions

Major:

argatroban avapritinib

Applies to: argatroban and avapritinib

Using avapritinib together with argatroban may increase the risk of bleeding. In clinical studies, treatment with avapritinib alone has been associated with severe and sometimes fatal hemorrhage.

Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.

Contact your doctor if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as:

  • dizziness
  • lightheadedness
  • red or black, tarry stools
  • coughing up or vomiting fresh or dried blood that looks like coffee grounds
  • headache
  • weakness

You should also seek immediate medical attention if you develop a severe headache, vision problems, drowsiness, and/or weakness in a specific area such as one side of the face or body, an arm, or even a small area like the tongue, as these may be signs and symptoms of bleeding in the brain.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Major food/lifestyle interactions

Major:

avapritinib Food/Lifestyle

Applies to: avapritinib

Avapritinib should be taken on an empty stomach, one hour before or two hours after a meal.

Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with avapritinib unless directed otherwise by your doctor.

Grapefruit juice can increase the blood levels of avapritinib. This may increase the risk and/or severity of serious side effects such as:

  • bleeding in the brain
  • cognitive impairment (forgetfulness, confusion, trouble thinking)
  • changes in mood or behavior
  • hallucinations
  • fluid retention or swelling
  • decreases in blood cell counts

You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts.

Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

10 potential interactions Applies to: 9 conditions, including Aortic Aneurysm, Liver Disease, Bleeding Disorder, Thrombocytopenia, and Cerebral Aneurysm.

Aortic Aneurysm

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Aortic Aneurysm.

Serious and fatal intracranial hemorrhage has been reported in patients treated with avapritinib. Patient conditions and risk factors for intracranial hemorrhage include a history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. In patients with advanced systemic mastocytosis (AdvSM), ensure platelet counts are performed prior to treatment, and then as recommended during therapy. Do not initiate treatment in patients with AdvSM if platelet counts are less than 50 x 10(9)/L.

Bleeding Disorder

Major:

argatroban

Argatroban has a major potential interaction with Bleeding Disorder.

The use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.

Cerebral Aneurysm

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Cerebral Aneurysm.

Serious and fatal intracranial hemorrhage has been reported in patients treated with avapritinib. Patient conditions and risk factors for intracranial hemorrhage include a history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. In patients with advanced systemic mastocytosis (AdvSM), ensure platelet counts are performed prior to treatment, and then as recommended during therapy. Do not initiate treatment in patients with AdvSM if platelet counts are less than 50 x 10(9)/L.

Cerebral Vascular Disorder

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Cerebral Vascular Disorder.

Serious and fatal intracranial hemorrhage has been reported in patients treated with avapritinib. Patient conditions and risk factors for intracranial hemorrhage include a history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. In patients with advanced systemic mastocytosis (AdvSM), ensure platelet counts are performed prior to treatment, and then as recommended during therapy. Do not initiate treatment in patients with AdvSM if platelet counts are less than 50 x 10(9)/L.

Coagulation Defects and Disorders

Major:

argatroban

Argatroban has a major potential interaction with Coagulation Defects and Disorders.

The use of thrombin inhibitors is contraindicated in the presence of active major bleeding. Additionally, these drugs should be used with caution in patients with disease states associated with an increased risk of bleeding.

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Coagulation Defects and Disorders.

Serious and fatal intracranial hemorrhage has been reported in patients treated with avapritinib. Patient conditions and risk factors for intracranial hemorrhage include a history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. In patients with advanced systemic mastocytosis (AdvSM), ensure platelet counts are performed prior to treatment, and then as recommended during therapy. Do not initiate treatment in patients with AdvSM if platelet counts are less than 50 x 10(9)/L.

Hemorrhagic Stroke

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Hemorrhagic Stroke.

Serious and fatal intracranial hemorrhage has been reported in patients treated with avapritinib. Patient conditions and risk factors for intracranial hemorrhage include a history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. In patients with advanced systemic mastocytosis (AdvSM), ensure platelet counts are performed prior to treatment, and then as recommended during therapy. Do not initiate treatment in patients with AdvSM if platelet counts are less than 50 x 10(9)/L.

Liver Disease

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Liver Disease.

Exposure to avapritinib is increased in patients with severe hepatic impairment and a lower starting dose is recommended for all indications. No dose adjustment is recommended for patients with mild (total bilirubin at the upper limit of normal [ULN] or less and AST greater than ULN, or total bilirubin greater than 1 to 1.5 x ULN and any AST) or moderate (total bilirubin greater than 1.5 to 3 x ULN and any AST) hepatic impairment.

Renal Dysfunction

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal impairment (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl <15 mL/min) on the pharmacokinetics of avapritinib is unknown, and the recommended dose of avapritinib has not been established for these patients. No dose adjustment is recommended for patients with mild or moderate renal impairment (CrCl) 30 to 89 mL/min estimated by Cockcroft-Gault].

Thrombocytopenia

Moderate:

avapritinib

Avapritinib has a moderate potential interaction with Thrombocytopenia.

Serious and fatal intracranial hemorrhage has been reported in patients treated with avapritinib. Patient conditions and risk factors for intracranial hemorrhage include a history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. In patients with advanced systemic mastocytosis (AdvSM), ensure platelet counts are performed prior to treatment, and then as recommended during therapy. Do not initiate treatment in patients with AdvSM if platelet counts are less than 50 x 10(9)/L.

Report options

Loading...
QR code containing a link to this page

More resources

argatroban

A total of 166 drugs are known to interact with argatroban.

avapritinib

A total of 486 drugs are known to interact with avapritinib.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer